中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

53 records (took 0.043 seconds)

    GLYCAN ARRAYS ON PTFE-LIKE ALUMINUM COATED GLASS SLIDES AND RELATED METHODS
    2.
    发明申请
    GLYCAN ARRAYS ON PTFE-LIKE ALUMINUM COATED GLASS SLIDES AND RELATED METHODS 审中-公开

    公开(公告)号：US20190277843A1

    公开(公告)日：2019-09-12

    申请号：US16365579

    申请日：2019-03-26

    Applicant: ACADEMIA SINICA

    Inventor： Chi-Huey WONG ,  Chung-YI WU ,  Susan Y. TSENG

    IPC: G01N33/553 ,  G01N33/58 ,  C40B50/14 ,  C40B40/12

    Abstract: Aluminum coated glass slides provide a novel glycan array platform. Specifically, aluminum coated glass slides increase sensitivity of fluorescent based assay methods. Additionally, aluminum coated glass slides allows for mass spectroscopic analysis of carbohydrates and provide a platform for examining activity of cellulases. The unique properties of ACG slides include: the metal oxide layer on the surface can be activated for grafting organic compounds such as modified oligosaccharides; the surface remains electrically conductive, and the grafted oligosaccharides can be simultaneously characterized by mass spectrometry and carbohydrate-binding assay; and the slides are more sensitive than transparent glass slides in binding analysis.

    HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
    3.
    发明申请
    HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS 审中-公开

    公开(公告)号：US20190099486A1

    公开(公告)日：2019-04-04

    申请号：US16175504

    申请日：2018-10-30

    Applicant: Academia Sinica

    Inventor： Chi-Huey WONG ,  Alice L. YU ,  Kun-Hsien LIN ,  Tai-Na WU

    IPC: A61K39/39 ,  C07H15/18 ,  A61K39/00

    Abstract: Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.

    ANTI-HER2 GLYCOANTIBODIES AND USES THEREOF
    4.
    发明申请
    ANTI-HER2 GLYCOANTIBODIES AND USES THEREOF 审中-公开

    公开(公告)号：US20180362662A1

    公开(公告)日：2018-12-20

    申请号：US16014255

    申请日：2018-06-21

    Applicant: Academia Sinica

    Inventor： Chi-Huey WONG ,  Chung-YI WU

    IPC: C07K16/40 ,  C12P21/00 ,  C07K16/28 ,  C07K16/32 ,  A61K31/517 ,  A61K39/395

    Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

    METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS
    7.
    发明申请
    METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS 审中-公开
    用于免疫病毒的方法和组合物

    公开(公告)号：US20150335728A1

    公开(公告)日：2015-11-26

    申请号：US14182296

    申请日：2014-02-18

    Applicant: Academia Sinica

    Inventor： Chi-Huey WONG ,  Che MA ,  Cheng-Chi WANG ,  Juine-Ruey CHEN

    IPC: A61K39/145 ,  C12N7/00

    CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/55505 ,  C07K16/1018 ,  C07K2317/76 ,  C12N7/00 ,  C12N2740/11034 ,  C12N2740/16034 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2770/24134 ,  Y02A50/386

    Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.

    Abstract translation: 提供了包含部分糖基化的病毒糖蛋白的免疫原性组合物，其用作抗病毒疫苗。 使用单糖，二糖或三糖基化的病毒表面糖蛋白和多肽配制的疫苗甚至可以跨毒株提供有效和广泛的防病毒保护。 公开了包含单糖基化血凝素多肽和由其产生的疫苗的药物组合物及其用于预防或治疗病毒感染的方法。 公开了用于流感病毒HA，NA和M2，RSV蛋白F，G和SH，登革病毒糖蛋白M或E，丙型肝炎病毒糖蛋白E1或E2和HIV糖蛋白gp120和gp41的方法和组合物。

    CRYSTAL STRUCTURE OF BIFUNCTIONAL TRANSGLYCOSYLASE PBP1B FROM E. COLI AND INHIBITORS THEREOF
    8.
    发明申请
    CRYSTAL STRUCTURE OF BIFUNCTIONAL TRANSGLYCOSYLASE PBP1B FROM E. COLI AND INHIBITORS THEREOF 审中-公开
    来自大肠杆菌及其抑制剂的双功能转移酶PBP1B的晶体结构

    公开(公告)号：US20150232417A1

    公开(公告)日：2015-08-20

    申请号：US14188678

    申请日：2014-02-24

    Applicant: ACADEMIA SINICA

    Inventor： Chi-Huey WONG ,  Che Alex MA ,  Ting-Jen Rachel CHENG ,  Wei-Chieh CHENG

    IPC: C07C235/64 ,  G01N33/573

    CPC classification number: C07C235/64 ,  C07C235/84 ,  C07K2299/00 ,  C12Q1/18 ,  C12Q1/48 ,  G01N33/573 ,  G01N2333/91102 ,  G01N2500/00 ,  G01N2500/04 ,  G01N2500/20

    Abstract: Crystal structure at 2.16 Å resolution of full-length Escherichia coli penicillin-binding protein 1b (PBP1b) in complex with its inhibitor moenomycin, is provided. 3D structures of amino acid residues involved in moenomycin binding and transglycosylation activity are identified. Binding sites for peptidoglycan synthesis inhibitors comprising amino acid residues from transglycosylase (TG), UvrB domain 2 homolog (UB2H) and transmembrane (TM) domains of PBP1b are identified at atomic level resolution. Rational drug design, based on the atomic coordinates, are disclosed. Methods for screening for antibiotics using anisotropic binding and transglycosylase inhibitor assays and novel antibiotics based on the screening assays are provided.

    Abstract translation: 提供了全长大肠杆菌青霉素结合蛋白1b（PBP1b）与其抑制剂新霉素复合物的分辨率为2.16Å的晶体结构。 鉴定涉及霉酚霉素结合和转糖基化活性的氨基酸残基的3D结构。 在原子级分辨率下鉴定了包含来自转糖苷酶（TG），UvrB结构域2同源物（UB2H）和PBP1b跨膜（TM）结构域的氨基酸残基的肽聚糖合成抑制剂的结合位点。 公开了基于原子坐标的合理药物设计。 提供了使用各向异性结合和转糖苷酶抑制剂测定法筛选抗生素的方法以及基于筛选试验的新型抗生素。

    IMPROVED CORONAVIRUS VACCINE
    9.
    发明公开
    IMPROVED CORONAVIRUS VACCINE 审中-公开

    公开(公告)号：US20240016917A1

    公开(公告)日：2024-01-18

    申请号：US18005573

    申请日：2022-04-12

    Applicant: ACADEMIA SINICA

    Inventor： Che MA ,  Chi-Huey WONG ,  Han-Yi HUANG

    IPC: A61K39/215 ,  A61P31/04

    CPC classification number: A61K39/215 ,  A61P31/04 ,  A61K2039/55505

    Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

Patent Agency Ranking